Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Second-generation piperazine derivatives as promising radiation countermeasures

V. Chmil, N. Živná, M. Milanová, A. Filipová, J. Pejchal, L. Prchal, D. Muthná, V. Řeháček, M. Řezáčová, J. Marek, A. Tichý, R. Havelek

. 2024 ; 15 (8) : 2855-2866. [pub] 20240711

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018032

The increasing threat of nuclear incidents and the widespread use of ionizing radiation (IR) in medical treatments underscore the urgent need for effective radiation countermeasures. Despite the availability of compounds such as amifostine, their clinical utility is significantly limited by adverse side effects and logistical challenges in administration. This study focuses on the synthesis and evaluation of novel piperazine derivatives as potential radioprotective agents, with the aim of overcoming the limitations associated with current countermeasures. We designed, synthesized, and evaluated a series of 1-(2-hydroxyethyl)piperazine derivatives. The compounds were assessed for cytotoxicity across a panel of human cell lines, and for their radioprotective effects in the MOLT-4 lymphoblastic leukemia cell line and in peripheral blood mononuclear cells (PBMCs) exposed to gamma radiation. The radioprotective efficacy was further quantified using the dicentric chromosome assay (DCA) to measure DNA damage mitigation. Among the synthesized derivatives, compound 6 demonstrated the most significant radioprotective effects in vitro, with minimal cytotoxicity across the tested cell lines. Compound 3 also showed notable efficacy, particularly in reducing dicentric chromosomes, thus indicating its potential to mitigate DNA damage from IR. Both compounds exhibited superior safety profiles and effectiveness compared to amifostine, suggesting their potential as more viable radioprotective agents. This study highlights the development of novel piperazine derivatives with promising radioprotective properties. Compound 6 emerged as the leading candidate, offering an optimal balance between efficacy and safety, with compound 3 also displaying significant potential. These findings support the further development and clinical evaluation of these compounds as safer, and more effective radiation countermeasures.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018032
003      
CZ-PrNML
005      
20241016081811.0
007      
ta
008      
241008s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1039/d4md00311j $2 doi
035    __
$a (PubMed)39149108
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Chmil, Vojtěch $u Department of Radiobiology, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic $1 https://orcid.org/0000000235429080
245    10
$a Second-generation piperazine derivatives as promising radiation countermeasures / $c V. Chmil, N. Živná, M. Milanová, A. Filipová, J. Pejchal, L. Prchal, D. Muthná, V. Řeháček, M. Řezáčová, J. Marek, A. Tichý, R. Havelek
520    9_
$a The increasing threat of nuclear incidents and the widespread use of ionizing radiation (IR) in medical treatments underscore the urgent need for effective radiation countermeasures. Despite the availability of compounds such as amifostine, their clinical utility is significantly limited by adverse side effects and logistical challenges in administration. This study focuses on the synthesis and evaluation of novel piperazine derivatives as potential radioprotective agents, with the aim of overcoming the limitations associated with current countermeasures. We designed, synthesized, and evaluated a series of 1-(2-hydroxyethyl)piperazine derivatives. The compounds were assessed for cytotoxicity across a panel of human cell lines, and for their radioprotective effects in the MOLT-4 lymphoblastic leukemia cell line and in peripheral blood mononuclear cells (PBMCs) exposed to gamma radiation. The radioprotective efficacy was further quantified using the dicentric chromosome assay (DCA) to measure DNA damage mitigation. Among the synthesized derivatives, compound 6 demonstrated the most significant radioprotective effects in vitro, with minimal cytotoxicity across the tested cell lines. Compound 3 also showed notable efficacy, particularly in reducing dicentric chromosomes, thus indicating its potential to mitigate DNA damage from IR. Both compounds exhibited superior safety profiles and effectiveness compared to amifostine, suggesting their potential as more viable radioprotective agents. This study highlights the development of novel piperazine derivatives with promising radioprotective properties. Compound 6 emerged as the leading candidate, offering an optimal balance between efficacy and safety, with compound 3 also displaying significant potential. These findings support the further development and clinical evaluation of these compounds as safer, and more effective radiation countermeasures.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Živná, Natálie $u Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic $u Biomedical Research Centre, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic
700    1_
$a Milanová, Marcela $u Department of Radiobiology, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic $1 https://orcid.org/0000000223396197 $7 xx0252799
700    1_
$a Filipová, Alžběta $u Department of Radiobiology, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic $1 https://orcid.org/0000000238496449 $7 ola2018976993
700    1_
$a Pejchal, Jaroslav $u Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic
700    1_
$a Prchal, Lukáš $u Biomedical Research Centre, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic
700    1_
$a Muthná, Darina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University Simkova 870 500 03 Hradec Kralove Czech Republic havelekr@lfhk.cuni.cz
700    1_
$a Řeháček, Vít $u Transfusion Department, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove - Novy Hradec Kralove Czech Republic
700    1_
$a Řezáčová, Martina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University Simkova 870 500 03 Hradec Kralove Czech Republic havelekr@lfhk.cuni.cz $1 https://orcid.org/0000000153702290 $7 nlk20020124956
700    1_
$a Marek, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic $u Department of Epidemiology, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic
700    1_
$a Tichý, Aleš $u Department of Radiobiology, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic $u Biomedical Research Centre, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic $1 https://orcid.org/0000000282625703 $7 xx0135624
700    1_
$a Havelek, Radim $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University Simkova 870 500 03 Hradec Kralove Czech Republic havelekr@lfhk.cuni.cz $1 https://orcid.org/0000000305281334 $7 xx0230947
773    0_
$w MED00208004 $t RSC medicinal chemistry $x 2632-8682 $g Roč. 15, č. 8 (2024), s. 2855-2866
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39149108 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241016081807 $b ABA008
999    __
$a ok $b bmc $g 2196440 $s 1229983
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 15 $c 8 $d 2855-2866 $e 20240711 $i 2632-8682 $m RSC medicinal chemistry $n RSC Med Chem $x MED00208004
LZP    __
$a Pubmed-20241008

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...